A case for introducing insulin early in the treatment of type 2 diabetes mellitus

Insulin

Volumn 1, Issue 2, 2006, Pages 65-69

  Westphal, Sydney A ^a   Palumbo, Pasquale J ^b  

^a MARICOPA MEDICAL CENTER   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

insulin deficiency; insulin resistance; insulin therapy; type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING DRUG; METFORMIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING DRUG; SULFONYLUREA;

ARTICLE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE COURSE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; LIVER; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SHORT COURSE THERAPY; WEIGHT GAIN;

EID: 33745500076     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(06)80012-6     Document Type: Article

References (35)

1. [published correction appears in Diabetes. 1996;45:1655]. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type 2 diabetes: A progressive disease. Diabetes 44 (1995) 1249-1258
2. Nathan D.M. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347 (2002) 1342-1349
3. Gerich J.E. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 78 (2003) 447-456
4. Weyer C., Bogardus C., Mott D.M., and Pratley R.E. The natural history of insulin secretary dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104 (1999) 787-794
5. Matthews D.R., Cull C.A., Stratton I.M., et al., UK Prospective Diabetes Study (UKPDS) Group. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 15 (1998) 297-303
6. Saad M.F., Knowler W.C., Pettitt D.J., et al. Sequential changes in serum insulin concentration during development of non-insulindependent diabetes. Lancet 1 (1989) 1356-1359
7. Levy J., Atkinson A.B., Bell P.M., et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: The 10-year follow-up of the Belfast Diet Study. Diabet Med 15 (1998) 290-296
8. Turner R.C., Cull C.A., Frighi V., Holman R.R., and UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
9. Butler A.E., Janson J., Bonner-Weir S., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
10. Deng S., Vatamaniuk M., Huang X., et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53 (2004) 624-632
11. Kahn S.E. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 4047-4058
12. Poitout V., and Robertson R.P. Minireview: Secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 143 (2002) 339-342
13. Brown J.B., Nichols G.A., and Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 27 (2004) 1535-1540
14. Garvey W.T., Olefsky J.M., Griffin J., et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34 (1985) 222-234
15. Glaser B., Leibovich G., Nesher R., et al. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes. Acto Endocrinol (Copenh) 118 (1988) 365-373
16. Karvestedt L., Andersson G., Efendic S., and Grill V. A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment. J Intern Med 251 (2002) 307-316
17. Ilkova H., Glaser B., Tunckale A., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 20 (1997) 1353-1356
18. Ryan E.A., Imes S., and Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27 (2004) 1028-1032
19. Li Y., Xu W., Liao Z., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 27 (2004) 2597-2602
20. Kayashima T., Yamaguchi K., Konno Y., et al. Effects of early introduction of intensive insulin therapy on the clinical course in nonobese NIDDM patients. Diabet Res Clin Prod 28 (1995) 119-125
21. Alvarsson M., Sundkvist G., Lager I., et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26 (2003) 2231-2237
22. Scarlett J.A., Gray R.S., Griffin J., et al. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 5 (1982) 353-363
23. Henry R.R., Gumbiner B., Ditzler T., et al. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 16 (1993) 21-31
24. Mayorov A.Y., Naumenkova I.V., Antsiferov M.B., and Dedov I.I. Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients. Diabet Res Clin Pract 68 Suppl 1 (2005) S54-S59
25. [published correction appears in Lancet. 1999;354:602]. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
27. Anderson Jr. J.H., Brunelle R.L., Keohane P., et al., Multicenter Insulin Lispro Study Group. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 157 (1997) 1249-1255
28. Yki Jarvinen H., Dressler A., Ziemen M., and HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23 (2000) 1130-1136
29. Yki Jarvinen H., Ryysy L., Nikkila K., et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: A randomized, controlled trial. Ann Intern Med 130 (1999) 389-396
30. Welborn T.A., and Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 2 (1979) 154-160
31. Fontbonne A.M., and Eschwege E.M. Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care 14 (1991) 461-469
32. Pyorala M., Miettinen H., Laakso M., and Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: The 22 year follow-up results of the Helsinki Policemen Study. Circulation 98 (1998) 398-404
33. [published correction appears in Cardiovasc Res. 1997;36:460]. Malmberg K., Ryden L., Hamsten A., et al. Mortality prediction in diabetes patients with myocardial infarction: Experiences from the DIGAMI Study. Cardiovasc Res 34 (1997) 248-253
34. Nathan D.M., Cleary P.A., Backlund J.Y., et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
35. Edelman S.V., and Morello C.M. Strategies for insulin therapy in type 2 diabetes. South Med J 98 (2005) 363-371